Lemtrada and Infusion site extravasation - a phase IV clinical study of FDA data

Summary:

Infusion site extravasation is reported as a side effect among people who take Lemtrada (alemtuzumab), especially for people who are female, 30-39 old, have been taking the drug for < 1 month also take Tylenol, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Infusion site extravasation when taking Lemtrada. It is created by eHealthMe based on reports of 8,297 people who have side effects when taking Lemtrada from the FDA, and is updated regularly.

What is Lemtrada?

Lemtrada has active ingredients of alemtuzumab. eHealthMe is studying from 8,317 Lemtrada users. Check the latest studies of Lemtrada.

What is Infusion site extravasation?

Infusion site extravasation (flow of (blood or lymph) from infusion site) is found to be associated with 649 drugs and 589 conditions by eHealthMe. Check the latest studies of Infusion site extravasation.

On Jul, 14, 2026

8,297 people reported to have side effects when taking Lemtrada.
Among them, 19 people (0.23%) have Infusion site extravasation.

Could Lemtrada cause Infusion site extravasation?

Among these 19 people:

How long have people been on Lemtrada when they have Infusion site extravasation? *

What is the gender of people who have Infusion site extravasation when taking Lemtrada? *

female: 72.22 %
male: 27.78 %

What is the age of people who have Infusion site extravasation when taking Lemtrada? *

What are other drugs people take besides Lemtrada? *

What are other side effects people have besides Infusion site extravasation? *

Headache (pain in head): 11 people, 57.89%
Lymphocyte Count Decreased: 9 people, 47.37%
Itching: 9 people, 47.37%
Fatigue (feeling of tiredness): 9 people, 47.37%
Rashes (redness): 9 people, 47.37%
Nausea (feeling of having an urge to vomit): 8 people, 42.11%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 7 people, 36.84%
Joint Pain: 6 people, 31.58%
Hypoaesthesia (reduced sense of touch or sensation): 6 people, 31.58%
Infection: 5 people, 26.32%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 13 people, 68.42%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 31.58%
Neuralgia (pain in one or more nerves): 1 person, 5.26%
Infusion Related Reaction: 1 person, 5.26%
Headache (pain in head): 1 person, 5.26%
Birth Control: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Lemtrada and have Infusion site extravasation?

- Check whether Infusion site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lemtrada:

Lemtrada (8,317 reports)

Browse all side effects of Lemtrada:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site extravasation:

Infusion site extravasation (649 drugs)

Browse all the conditions that are associated with Infusion site extravasation:

Infusion site extravasation (589 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Lemtrada) and Lemtrada (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.